Sarcopenia Marketed and Pipeline Drugs Assessment, Clinical Trials, Social Media and Competitive Landscape, 2022 Update

Sarcopenia Marketed and Pipeline Drugs Assessment, Clinical Trials, Social Media and Competitive Landscape, 2022 Update

Summary

This reports provides a data-driven overview of the current and future competitive landscape in Sarcopenia therapeutics.

Synopsis

There are 51 million cases of sarcopenia in the 16 countries covered in GlobalData’s epidemiology forecast for sarcopenia.

There is no FDA approved marketed product for the treatment of sarcopenia.

The sarcopenia pipeline consists of 41 pharmaceuticals spanning all stages of development. However, none of these molecules are present in the late-stage pipeline.

Non-industrial sponsors dominate clinical trial development in sarcopenia, with the US emerging as the key country for conducting trials in sarcopenia.

Deals involving licensing sarcopenia assets are the most common type of deal globally.

With the current sarcopenia market being completely untapped, there remains a lot of potential for new market entrants.

Scope

GlobalData’s Sarcopenia Marketed and Pipeline Drugs Assessment, Clinical Trials, Social Media and Competitive Landscape, 2022 Update combines data from the Pharma Intelligence Center with in-house analyst expertise to provide a competitive assessment of the disease marketplace.

Components of the report include -

Disease Landscape

Disease Overview

Epidemiology Overview

Treatment Overview

Marketed Products Assessment

Pipeline Assessment

Breakdown by Development Stage, Mechanism of Action, Molecule Type, Route of Administration

Late-to-mid-stage Pipeline Drugs

Phase Transition Success Rate and Likelihood of Approval

Clinical Trials Assessment

Breakdown of Trials by Phase, Status, Virtual Components, Sponsors, Geography, and Endpoint Status

Enrolment Analytics, Site Analytics, Feasibility Analysis

Deals Landscape

Mergers, Acquisitions, and Strategic Alliances by Region

Overview of Recent Deals

Commercial Assessment

Key Market Players

Future Market Catalysts

Reasons to Buy

• Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
• Develop business strategies by understanding the trends shaping and driving the Sarcopenia market.
• Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global Sarcopenia market in the future.
• Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
• Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
• Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.